<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367066</url>
  </required_header>
  <id_info>
    <org_study_id>D6420C00001</org_study_id>
    <nct_id>NCT02367066</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>A Single Centre, Double-blind, Randomised, Placebo-controlled, Cross-over Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX After Administration of Repeated Doses for 3 Days in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the Pharmacodynamics of oral AR-C165395XX after Administration of Repeated
      Doses for 3 days in Subjects with Type 2 Diabetes Mellitus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Single Centre, Double-blind, Randomised, Placebo-controlled, Cross-over Phase I Study to
      Assess the Pharmacodynamics of oral AR-C165395XX after Administration of Repeated Doses for 3
      days in Subjects with Type 2 Diabetes Mellitus
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Endpoint MMTT AUC(0-4h) for Plasma Glucose</measure>
    <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
    <description>MMTT=Mixed Meal Tolerance Test AUC=Area Under Curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Endpoint MMTT C_max for Plasma Glucose</measure>
    <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Endpoint GGI AUC(1-2h) for Plasma C-Peptide</measure>
    <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
    <description>GGI=Glucose and GLP1 infusion AUC=Area Under Curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint MMTT AUC(0-4h) for Plasma Insulin</measure>
    <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline MMTT AUC(0-4h) for Plasma Glucagon</measure>
    <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint MMTT AUC(0-4h) for Plasma C-Peptide</measure>
    <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint GGI AUC(0-1h) for Plasma Insulin</measure>
    <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint GGI AUC(1-2h) for Plasma Insulin</measure>
    <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint GGI AUC(0-1h) for Plasma Glucagon</measure>
    <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint GGI AUC(1-2h) for Plasma Glucagon</measure>
    <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint Fasting Beta-cell Responsiveness</measure>
    <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin at Endpoint</measure>
    <time_frame>Day 3 and Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma AZD1981 Concentration at Steady-State, C_ss,Max</measure>
    <time_frame>Days 2,3,8,9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Plasma AZD1081 Concentration, t_ss,Max</measure>
    <time_frame>Days 2,3,8,9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AZD1981 AUC(0-1h)</measure>
    <time_frame>Days 2,3,8,9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AZD1981 AUC(0-2h)</measure>
    <time_frame>Days 2,3,8,9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Plasma AZD1981 Concentration at Steady-State, C_ss,Min</measure>
    <time_frame>Days 2,3,8,9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AZD1981 AUC(1-2h)</measure>
    <time_frame>Days 2,3,8,9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Paracetamol Maximum Concentration, C_max</measure>
    <time_frame>Days 3,9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Plasma Paracetamol Concentration, t_max</measure>
    <time_frame>Days 3,9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Paracetamol AUC(0-t)</measure>
    <time_frame>Days 3,9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint GGI AUC(0-1h) for Plasma C-Peptide</measure>
    <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint GGI AUC(0-24h) for Plasma Glucose</measure>
    <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AZD1981 AUC(0-4h)</measure>
    <time_frame>Days 2,3,8,9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AZD1981 AUC(0-12h)</measure>
    <time_frame>Days 2,3,8,9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AZD1981 AUC(0-24h)</measure>
    <time_frame>Days 2,3,8,9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Plasma AZD1981 at Steady-State, CL_ss/F</measure>
    <time_frame>Days 2,3,8,9</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>AR-C165395XX + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st period AR-C165395XX 2nd period placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + AR-C165395XX</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1st period Placebo for AR-C165395XX 2nd period AR-C165395XX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AR-C165395XX</intervention_name>
    <description>Oral dose of AR-C165395XX (tablets)</description>
    <arm_group_label>AR-C165395XX + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral dose of placebo for AR-C165395XX (tablets)</description>
    <arm_group_label>Placebo + AR-C165395XX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Provision of informed consent

          -  Male or female of non-childbearing potential (postmenopausal, and/or have undergone
             hysterectomy and/or bilateral oophorectomy or salpingectomy/tubal ligation) aged ≥18.

          -  Patients with HbA1c ≥7.5 but ≤11% at enrolment visit (Visit 1)

          -  ody mass index &gt;19 to &lt;38 kg/m2

          -  he fasting plasma glucose should be in the range of 3-14 mmol/L (54-252 mg/dL,
             nclusive) on the morning of Visit 1.

          -  Clinical diagnosis of type 2 diabetes mellitus

          -  Metformin as only anti-diabetic treatment, at least for the last 3 months

        Exclusion Criteria:

          -  History or sign of any clinically significant disease or disorder which, in the
             opinion f the investigator, may either put the subject at risk because of
             participation in the sudy, or influence the results or the subject's ability to
             participate in the study

          -  Any clinically significant abnormalities in clinical chemistry, haematology or
             urinalysis results as judged by the investigator

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) laboratory results
             &gt;3x upper level of normal range (ULN) Clinical diagnosis of Type 1 diabetes mellitus
             and/or history of diabetic ketoacidosis or positive Glutamic Acid Decarboxylase
             Autoantibodies test (GAD antibodies test).

          -  Patients treated with single Insulin therapy within the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liliana Uribe-Bruce, MD, MCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institute for Clinical Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stanko Skrtic, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Mölndal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <results_first_submitted>March 22, 2016</results_first_submitted>
  <results_first_submitted_qc>May 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2016</results_first_posted>
  <last_update_submitted>May 17, 2016</last_update_submitted>
  <last_update_submitted_qc>May 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>patients</keyword>
  <keyword>glycaemic control on metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Male or female T2DM patients of non-childbearing potential aged &gt;=18 with 7.5&lt;=HbA1c&lt;=11%, 19&lt;BMI&lt;38 kg/m2, fasting plasma glucose in range 3-14 mmol/L and on Metformin as the only anti-diabetic treatment for the last 3 months</recruitment_details>
      <pre_assignment_details>30 patients were enrolled in the study. 10 of these were screen failures, leaving 20 patients who started the started the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD1981-Placebo</title>
          <description>Sequence AZD1981-Placebo</description>
        </group>
        <group group_id="P2">
          <title>Placebo-AZD1981</title>
          <description>Sequence Placebo-AZD1981</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD1981-Placebo</title>
          <description>Sequence AZD1981-Placebo</description>
        </group>
        <group group_id="B2">
          <title>Placebo-AZD1981</title>
          <description>Sequence Placebo-AZD1981</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.10" spread="9.10"/>
                    <measurement group_id="B2" value="54.80" spread="6.80"/>
                    <measurement group_id="B3" value="54.00" spread="7.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.28" spread="18.95"/>
                    <measurement group_id="B2" value="87.59" spread="20.36"/>
                    <measurement group_id="B3" value="87.44" spread="19.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.80" spread="10.70"/>
                    <measurement group_id="B2" value="164.90" spread="12.59"/>
                    <measurement group_id="B3" value="165.80" spread="11.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.13" spread="3.58"/>
                    <measurement group_id="B2" value="32.13" spread="5.37"/>
                    <measurement group_id="B3" value="31.63" spread="4.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>T2DM disease duration</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.30" spread="4.24"/>
                    <measurement group_id="B2" value="8.60" spread="5.02"/>
                    <measurement group_id="B3" value="9.50" spread="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Metformin Daily Dose</title>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1765.00" spread="473.78"/>
                    <measurement group_id="B2" value="1895.00" spread="390.48"/>
                    <measurement group_id="B3" value="1830.00" spread="427.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <description>Percentage of glycosylated hemoglobin, DCCT</description>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.50" spread="1.24"/>
                    <measurement group_id="B2" value="9.30" spread="0.88"/>
                    <measurement group_id="B3" value="9.40" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Endpoint MMTT AUC(0-4h) for Plasma Glucose</title>
        <description>MMTT=Mixed Meal Tolerance Test AUC=Area Under Curve</description>
        <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
        <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint MMTT AUC(0-4h) for Plasma Glucose</title>
          <description>MMTT=Mixed Meal Tolerance Test AUC=Area Under Curve</description>
          <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="1.14"/>
                    <measurement group_id="O2" value="0.98" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>1-sided</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>0.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Endpoint MMTT C_max for Plasma Glucose</title>
        <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
        <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint MMTT C_max for Plasma Glucose</title>
          <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="1.12"/>
                    <measurement group_id="O2" value="0.97" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>1-sided</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>0.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Endpoint GGI AUC(1-2h) for Plasma C-Peptide</title>
        <description>GGI=Glucose and GLP1 infusion AUC=Area Under Curve</description>
        <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
        <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint GGI AUC(1-2h) for Plasma C-Peptide</title>
          <description>GGI=Glucose and GLP1 infusion AUC=Area Under Curve</description>
          <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
          <units>h*pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="1.17"/>
                    <measurement group_id="O2" value="1.06" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <p_value_desc>1-sided</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>0.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint MMTT AUC(0-4h) for Plasma Insulin</title>
        <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
        <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint MMTT AUC(0-4h) for Plasma Insulin</title>
          <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
          <units>h*mU/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="1.23"/>
                    <measurement group_id="O2" value="1.08" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>1-sided</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>0.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline MMTT AUC(0-4h) for Plasma Glucagon</title>
        <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
        <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline MMTT AUC(0-4h) for Plasma Glucagon</title>
          <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
          <units>h*pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="1.19"/>
                    <measurement group_id="O2" value="0.96" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <p_value_desc>1-sided</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>1.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint MMTT AUC(0-4h) for Plasma C-Peptide</title>
        <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
        <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint MMTT AUC(0-4h) for Plasma C-Peptide</title>
          <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
          <units>h*pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="1.15"/>
                    <measurement group_id="O2" value="1.09" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <p_value_desc>1-sided</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>0.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint GGI AUC(0-1h) for Plasma Insulin</title>
        <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
        <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint GGI AUC(0-1h) for Plasma Insulin</title>
          <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
          <units>h*mU/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="1.19"/>
                    <measurement group_id="O2" value="1.07" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint GGI AUC(1-2h) for Plasma Insulin</title>
        <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
        <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint GGI AUC(1-2h) for Plasma Insulin</title>
          <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
          <units>h*mU/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="1.25"/>
                    <measurement group_id="O2" value="1.04" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <p_value_desc>1-sided</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Geometric LS MEan Ratio</param_type>
            <param_value>1.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint GGI AUC(0-1h) for Plasma Glucagon</title>
        <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
        <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint GGI AUC(0-1h) for Plasma Glucagon</title>
          <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
          <units>h*mmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="1.08"/>
                    <measurement group_id="O2" value="0.97" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint GGI AUC(1-2h) for Plasma Glucagon</title>
        <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
        <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint GGI AUC(1-2h) for Plasma Glucagon</title>
          <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
          <units>h*mmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="1.06"/>
                    <measurement group_id="O2" value="0.99" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>1-sided</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>1.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint Fasting Beta-cell Responsiveness</title>
        <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
        <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint Fasting Beta-cell Responsiveness</title>
          <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
          <units>10^-9*(L/kg)*min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                    <measurement group_id="O2" value="-0.00" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.45</p_value>
            <p_value_desc>2-sided</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Insulin at Endpoint</title>
        <time_frame>Day 3 and Day 9</time_frame>
        <population>One value per subject and treatment. AZD1981 value calculated at Day 3 if subject in sequence AZD1981-Placebo or at Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day 3 if subject in sequence Placebo-AZD1981 or at Day 9 if subject in sequence AZD1981-Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Insulin at Endpoint</title>
          <population>One value per subject and treatment. AZD1981 value calculated at Day 3 if subject in sequence AZD1981-Placebo or at Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day 3 if subject in sequence Placebo-AZD1981 or at Day 9 if subject in sequence AZD1981-Placebo.</population>
          <units>UIU/ML</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.70" spread="1.48"/>
                    <measurement group_id="O2" value="11.40" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma AZD1981 Concentration at Steady-State, C_ss,Max</title>
        <time_frame>Days 2,3,8,9</time_frame>
        <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
        <group_list>
          <group group_id="O1">
            <title>MMTT</title>
            <description>MMTT (Mixed Meal Tolerance Test)</description>
          </group>
          <group group_id="O2">
            <title>GGI (Graded Glucose and GLP1 Infusion)</title>
            <description>GGI (Graded glucose and GLP1 infusion)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma AZD1981 Concentration at Steady-State, C_ss,Max</title>
          <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2507" spread="71.09"/>
                    <measurement group_id="O2" value="3662" spread="86.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Plasma AZD1081 Concentration, t_ss,Max</title>
        <time_frame>Days 2,3,8,9</time_frame>
        <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
        <group_list>
          <group group_id="O1">
            <title>MMTT</title>
            <description>MMTT (Mixed Meal Tolerance Test)</description>
          </group>
          <group group_id="O2">
            <title>GGI (Graded Glucose and GLP1 Infusion)</title>
            <description>GGI (Graded Glucose and GLP1 infusion)</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Plasma AZD1081 Concentration, t_ss,Max</title>
          <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma AZD1981 AUC(0-1h)</title>
        <time_frame>Days 2,3,8,9</time_frame>
        <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
        <group_list>
          <group group_id="O1">
            <title>MMTT</title>
            <description>MMTT (Mixed Meal Tolerance Test)</description>
          </group>
          <group group_id="O2">
            <title>GGI (Graded Glucose and GLP1 Infusion)</title>
            <description>GGI (Graded Glucose and GLP1 Infusion)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma AZD1981 AUC(0-1h)</title>
          <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="701.30" spread="122.30"/>
                    <measurement group_id="O2" value="2061" spread="74.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma AZD1981 AUC(0-2h)</title>
        <time_frame>Days 2,3,8,9</time_frame>
        <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
        <group_list>
          <group group_id="O1">
            <title>MMTT</title>
            <description>Mixed Meal Tolerance Test (MMTT)</description>
          </group>
          <group group_id="O2">
            <title>GGI (Graded Glucose and GLP1 Infusion)</title>
            <description>GGI (Graded Glucose and GLP1 Infusion)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma AZD1981 AUC(0-2h)</title>
          <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2071" spread="97.56"/>
                    <measurement group_id="O2" value="5016" spread="75.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Plasma AZD1981 Concentration at Steady-State, C_ss,Min</title>
        <time_frame>Days 2,3,8,9</time_frame>
        <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
        <group_list>
          <group group_id="O1">
            <title>MMTT</title>
            <description>MMTT (Mixed Meal Tolerance Test)</description>
          </group>
          <group group_id="O2">
            <title>GGI (Graded Glucose and GLP1 Infusion)</title>
            <description>GGI (Graded Glucose and GLP1 Infusion)</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Plasma AZD1981 Concentration at Steady-State, C_ss,Min</title>
          <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.40" spread="39.12"/>
                    <measurement group_id="O2" value="376.20" spread="83.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma AZD1981 AUC(1-2h)</title>
        <time_frame>Days 2,3,8,9</time_frame>
        <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
        <group_list>
          <group group_id="O1">
            <title>MMTT</title>
            <description>MMTT (Mixed Meal Tolerance Test)</description>
          </group>
          <group group_id="O2">
            <title>GGI (Graded Glucose and GLP1 Infusion)</title>
            <description>GGI (Graded Glucose and GLP1 Infusion)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma AZD1981 AUC(1-2h)</title>
          <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1344" spread="88.76"/>
                    <measurement group_id="O2" value="2936" spread="78.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Paracetamol Maximum Concentration, C_max</title>
        <time_frame>Days 3,9</time_frame>
        <population>One value per subject and treatment. AZD1981 value calculated at Day 3 if subject in sequence AZD1981-Placebo or at Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day 3 if subject in sequence Placebo-AZD1981 or at Day 9 if subject in sequence AZD1981-Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Paracetamol Maximum Concentration, C_max</title>
          <population>One value per subject and treatment. AZD1981 value calculated at Day 3 if subject in sequence AZD1981-Placebo or at Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day 3 if subject in sequence Placebo-AZD1981 or at Day 9 if subject in sequence AZD1981-Placebo.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8074" spread="37.32"/>
                    <measurement group_id="O2" value="7899" spread="30.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Plasma Paracetamol Concentration, t_max</title>
        <time_frame>Days 3,9</time_frame>
        <population>One value per subject and treatment. AZD1981 value calculated at Day 3 if subject in sequence AZD1981-Placebo or at Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day 3 if subject in sequence Placebo-AZD1981 or at Day 9 if subject in sequence AZD1981-Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Plasma Paracetamol Concentration, t_max</title>
          <population>One value per subject and treatment. AZD1981 value calculated at Day 3 if subject in sequence AZD1981-Placebo or at Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day 3 if subject in sequence Placebo-AZD1981 or at Day 9 if subject in sequence AZD1981-Placebo.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O2" value="3.50" lower_limit="1.00" upper_limit="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Paracetamol AUC(0-t)</title>
        <time_frame>Days 3,9</time_frame>
        <population>One value per subject and treatment. AZD1981 value calculated at Day 3 if subject in sequence AZD1981-Placebo or at Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day 3 if subject in sequence Placebo-AZD1981 or at Day 9 if subject in sequence AZD1981-Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Paracetamol AUC(0-t)</title>
          <population>One value per subject and treatment. AZD1981 value calculated at Day 3 if subject in sequence AZD1981-Placebo or at Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day 3 if subject in sequence Placebo-AZD1981 or at Day 9 if subject in sequence AZD1981-Placebo.</population>
          <units>h*ng/ML</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19730" spread="46.64"/>
                    <measurement group_id="O2" value="18850" spread="26.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint GGI AUC(0-1h) for Plasma C-Peptide</title>
        <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
        <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint GGI AUC(0-1h) for Plasma C-Peptide</title>
          <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
          <units>h*pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="1.16"/>
                    <measurement group_id="O2" value="1.03" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint GGI AUC(0-24h) for Plasma Glucose</title>
        <time_frame>Day -1 to Day 3 and Day 6 to Day 9</time_frame>
        <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1981</title>
            <description>AZD1981, oral tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint GGI AUC(0-24h) for Plasma Glucose</title>
          <population>One value per subject and treatment. AZD1981 value calculated at Day -1 to Day 3 if subject in sequence AZ1981-Placebo or at Day 6 to Day 9 if subject in sequence Placebo-AZD1981. Placebo value calculated at Day -1 to Day 3 if subject in sequence Placebo-AZD1981 and at Day 6 to Day 9 if subject in sequence AZD1981-Placebo.</population>
          <units>h*mmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="1.09"/>
                    <measurement group_id="O2" value="0.97" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma AZD1981 AUC(0-4h)</title>
        <time_frame>Days 2,3,8,9</time_frame>
        <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
        <group_list>
          <group group_id="O1">
            <title>MMTT</title>
            <description>MMTT (Mixed Meal Tolerance Test)</description>
          </group>
          <group group_id="O2">
            <title>GGI (Graded Glucose and GLP1 Infusion)</title>
            <description>GGI (Graded Glucose and GLP1 Infusion)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma AZD1981 AUC(0-4h)</title>
          <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5793" spread="53.96"/>
                    <measurement group_id="O2" value="NA">PK not measured for this time interval</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma AZD1981 AUC(0-12h)</title>
        <time_frame>Days 2,3,8,9</time_frame>
        <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
        <group_list>
          <group group_id="O1">
            <title>MMTT</title>
            <description>MMTT (Mixed Meal Tolerance Test)</description>
          </group>
          <group group_id="O2">
            <title>GGI (Graded Glucose and GLP1 Infusion)</title>
            <description>GGI (Graded Glucose and GLP1 Infusion)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma AZD1981 AUC(0-12h)</title>
          <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12460" spread="36.79"/>
                    <measurement group_id="O2" value="NA">PK not measured for this time interval</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma AZD1981 AUC(0-24h)</title>
        <time_frame>Days 2,3,8,9</time_frame>
        <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
        <group_list>
          <group group_id="O1">
            <title>MMTT</title>
            <description>MMTT (Mixed Meal Tolerance Test)</description>
          </group>
          <group group_id="O2">
            <title>GGI (Graded Glucose and GLP1 Infusion)</title>
            <description>GGI (Graded Glucose and GLP1 Infusion)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma AZD1981 AUC(0-24h)</title>
          <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24930" spread="36.79"/>
                    <measurement group_id="O2" value="NA">PK not measured for this time interval</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Oral Plasma AZD1981 at Steady-State, CL_ss/F</title>
        <time_frame>Days 2,3,8,9</time_frame>
        <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
        <group_list>
          <group group_id="O1">
            <title>MMTT</title>
            <description>MMTT (Mixed Meal Tolerance Test)</description>
          </group>
          <group group_id="O2">
            <title>GGI (Graded Glucose and GLP1 Infusion)</title>
            <description>GGI (Graded Glucose and GLP1 Infusion)</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Plasma AZD1981 at Steady-State, CL_ss/F</title>
          <population>One value per subject and method (MMTT/GGI). Value calculated on days 2 and 3 if subject in sequence AZD1981-Placebo or on days 8 and 9 if subject in sequence Placebo-AZD1981.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.94" spread="8.19"/>
                    <measurement group_id="O2" value="NA">PK not measured for this time interval</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD1981</title>
          <description>AZD1981, oral tablet</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo, oral tablet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel puncture site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vessel puncture site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Stanko Skrtic, MD, PhD</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

